Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOTF14
|
|||
| Drug Name |
MEDI3506
|
|||
| Synonyms |
Tozorakimab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 3 | [1] | |
| Company |
MedImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-33 (IL33) | Target Info | . | [1] |
| KEGG Pathway | Cytosolic DNA-sensing pathway | |||
| Influenza A | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.